LIVIVO - Search results -

Search results

Result 1 - 10 of total 183

Search options

Article ; Online: Predominance of visuoconstructive impairment after mild COVID-19?

Díez-Cirarda, María / Yus, Miguel / Matías-Guiu, Jorge / Matias-Guiu, Jordi A

2022 Volume 28, Issue 2, Page(s) 536–537

MeSH term(s)	Humans ; COVID-19 ; Memory ; Neuropsychological Tests
Language	English
Publishing date	2022-09-19
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	1330655-8
ISSN	1476-5578 ; 1359-4184
ISSN (online)	1476-5578
ISSN	1359-4184
DOI	10.1038/s41380-022-01797-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4812: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Amantadine and/or transcranial magnetic stimulation for fatigue associated with multiple sclerosis (FETEM): study protocol for a phase 3 randomised, double-blind, cross-over, controlled clinical trial.

Matias-Guiu, Jordi A / González-Rosa, Javier / Hernández, Miguel Ángel / Martínez-Ginés, Maria Luisa / Portolés, Antonio / Pérez-Macías, Natalia / Benito-León, Julián / Padrón, Iván / Prieto, Julio / Matias-Guiu, Jorge

BMJ open

2024 Volume 14, Issue 1, Page(s) e078661

Abstract: Introduction: Fatigue is one of the most disabling symptoms of multiple sclerosis (MS), and effective treatments are lacking. Amantadine is one of the most used treatments, although its efficacy is under debate. Transcranial magnetic stimulation (TMS) ... ...

Abstract	Introduction: Fatigue is one of the most disabling symptoms of multiple sclerosis (MS), and effective treatments are lacking. Amantadine is one of the most used treatments, although its efficacy is under debate. Transcranial magnetic stimulation (TMS) is a promising intervention that has shown positive effects in some preliminary investigations. We aim to investigate the effect of 6 weeks of amantadine and/or TMS in fatigue due to MS. Methods and analysis: The study is a national, multicentre, phase 3, randomised, double-blind, cross-over, placebo-controlled and sham-controlled clinical trial. Adult patients with relapsing-remitting MS, Expanded Disability Status Scale score of 1.5-4.5 and Fatigue Severity Score>4 are eligible for the trial. Participants will be randomised to one of the sequences of the study. Each sequence consists of four periods of 6 weeks of treatment and three washout periods of 12-18 weeks. All patients will receive all the combinations of therapies. The primary outcome is the Modified Fatigue Impact Scale. The secondary outcomes are the Symbol Digit Modalities Test (cognition), Beck Depression Inventory-II (depressive symptoms) and Short-Survey 12 (quality of life). Safety and cost-effectiveness will also be evaluated. An exploratory substudy including MRI and blood biomarkers will be conducted. Ethics and dissemination: The study is approved by the Ethics Committee of the Hospital Clinico San Carlos and the Spanish Agency of Medications and Medical Devices. All study findings will be published in scientific peer-reviewed journals and presented at relevant scientific conferences. Trial registration number: EudraCT 2021-004868-95; NCT05809414.
MeSH term(s)	Adult ; Humans ; Multiple Sclerosis/complications ; Multiple Sclerosis/drug therapy ; Transcranial Magnetic Stimulation ; Quality of Life ; Amantadine/therapeutic use ; Double-Blind Method ; Fatigue/therapy ; Fatigue/chemically induced ; Treatment Outcome ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic ; Clinical Trials, Phase III as Topic
Chemical Substances	Amantadine (BF4C9Z1J53)
Language	English
Publishing date	2024-01-04
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2023-078661
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cognitive dysfunction characteristics of multiple sclerosis with aging.

Vidorreta-Ballesteros, Lucía / Matias-Guiu, Jordi A / Delgado-Álvarez, Alfonso / Delgado-Alonso, Cristina / Valles-Salgado, María / Cuevas, Constanza / Gil-Moreno, María José / García-Ramos, Rocío / Montero-Escribano, Paloma / Matias-Guiu, Jorge

Multiple sclerosis and related disorders

2024 Volume 87, Page(s) 105678

Abstract: Background: We aimed to investigate the characteristics of cognitive impairment in older people with multiple sclerosis (MS).: Methods: Cross-sectional study that included participants that were examined with a common and comprehensive ... ...

Abstract	Background: We aimed to investigate the characteristics of cognitive impairment in older people with multiple sclerosis (MS). Methods: Cross-sectional study that included participants that were examined with a common and comprehensive neuropsychological protocol. The subjects were matched by sociodemographic variables and the following groups were generated for comparisons: young MS versus healthy controls (HC) (n = 246), old MS versus HC (n = 198), young MS vs old MS (n = 226), MS vs Alzheimer's disease (AD)(n = 70), and MS vs Parkinson's disease (PD) (n = 62). The ICCoDiMS criteria were used to define cognitive impairment in MS. Results: Cognitive impairment was more frequent in young than old patients (70.8 % vs 52.2 %). Attention and speed processing is the most frequent cognitive domain impaired in MS (54.9 % of young MS vs 32.7 % of old MS). The frequency of impairment in attention/processing speed (54.9 % vs 32.7 %) and episodic memory (27.9 % vs 14.3) was higher in the young group than in the old group. There were no statistically significant differences in the distribution of impairment in executive function (46.0 % vs 35.3 %), visuospatial (17.9 % vs 9.5 %), and language (12.4 % vs 17.7 %). In those patients meeting the criteria for cognitive impairment, young MS patients showed lower performance in attention/processing speed tests. Conversely, old MS patients showed lower performance in episodic memory, verbal fluency, and planning. There were no differences in the correlations between SDMT and other neuropsychological tests in young and old patients, which suggests similar cognitive processes underlying SDMT performance in both groups. There were differences between old MS and prodromal AD, especially in episodic memory, while the cognitive profile of old MS was largely shared with PD. Conclusions: Our study found that the cognitive profile of MS is defined by a characteristic impairment in attention and processing speed, which is present during the lifespan. The impairment in processing speed is less prominent in old age, whereas the impairment of other cognitive functions becomes more relevant. These findings suggest potential differences in the pathophysiological processes associated with cognitive impairment between young and old ages that warrant further investigation.
Language	English
Publishing date	2024-05-07
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2645330-7
ISSN	2211-0356 ; 2211-0348
ISSN (online)	2211-0356
ISSN	2211-0348
DOI	10.1016/j.msard.2024.105678
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Death Rate Due to COVID-19 in Alzheimer's Disease and Frontotemporal Dementia.

Matias-Guiu, Jordi A / Pytel, Vanesa / Matías-Guiu, Jorge

Journal of Alzheimer's disease : JAD

2020 Volume 78, Issue 2, Page(s) 537–541

Abstract: We aimed to evaluate the frequency and mortality of COVID-19 in patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD). We conducted an observational case series. We enrolled 204 patients, 15.2% of whom were diagnosed with COVID-19, and ...

Abstract	We aimed to evaluate the frequency and mortality of COVID-19 in patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD). We conducted an observational case series. We enrolled 204 patients, 15.2% of whom were diagnosed with COVID-19, and 41.9% of patients with the infection died. Patients with AD were older than patients with FTD (80.36±8.77 versus 72.00±8.35 years old) and had a higher prevalence of arterial hypertension (55.8% versus 26.3%). COVID-19 occurred in 7.3% of patients living at home, but 72.0% of those living at care homes. Living in care facilities and diagnosis of AD were independently associated with a higher probability of death. We found that living in care homes is the most relevant factor for an increased risk of COVID-19 infection and death, with AD patients exhibiting a higher risk than those with FTD.
MeSH term(s)	Age Factors ; Aged ; Aged, 80 and over ; Alzheimer Disease/complications ; Alzheimer Disease/mortality ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/mortality ; Female ; Frontotemporal Dementia/complications ; Frontotemporal Dementia/mortality ; Humans ; Hypertension/complications ; Independent Living ; Male ; Nursing Homes ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/mortality ; Prevalence ; Risk Factors
Keywords	covid19
Language	English
Publishing date	2020-10-13
Publishing country	Netherlands
Document type	Letter ; Observational Study
ZDB-ID	1440127-7
ISSN	1875-8908 ; 1387-2877
ISSN (online)	1875-8908
ISSN	1387-2877
DOI	10.3233/JAD-200940
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6084: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Editorial: The Use of Biomaterials With Stem and Precursor Cells in Diseases of the Central Nervous System; A Step to Clinical Trials.

Ramos-Zúñiga, Rodrigo / Guerrero-Cázares, Hugo / Gómez-Pinedo, Ulises / Matias-Guiu, Jorge

Frontiers in neurology

2021 Volume 12, Page(s) 654890

Language	English
Publishing date	2021-03-30
Publishing country	Switzerland
Document type	Editorial
ZDB-ID	2564214-5
ISSN	1664-2295
ISSN	1664-2295
DOI	10.3389/fneur.2021.654890
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Underpinnings of verbal fluency in Multiple Sclerosis.

Delgado-Álvarez, Alfonso / Delgado-Alonso, Cristina / Matías-Guiu, Jorge / Matias-Guiu, Jordi A

Multiple sclerosis and related disorders

2021 Volume 53, Page(s) 103056

Abstract: The cognitive and language processes underlying verbal fluency remain unclear. While some cognitive processes related to memory and executive functioning have been more associated with category and letter verbal fluency, other less studied aspects of ... ...

Abstract	The cognitive and language processes underlying verbal fluency remain unclear. While some cognitive processes related to memory and executive functioning have been more associated with category and letter verbal fluency, other less studied aspects of language ability could be also related. We discuss the contribution of the recent study by Lebkuecher and colleagues (2021) about the role of language in verbal fluency, and the data from other studies evaluating the cognitive and neuroimaging correlates of verbal fluency in MS.
MeSH term(s)	Executive Function ; Humans ; Language ; Multiple Sclerosis/complications ; Multiple Sclerosis/diagnostic imaging ; Neuropsychological Tests
Language	English
Publishing date	2021-05-29
Publishing country	Netherlands
Document type	Letter
ZDB-ID	2645330-7
ISSN	2211-0356 ; 2211-0348
ISSN (online)	2211-0356
ISSN	2211-0348
DOI	10.1016/j.msard.2021.103056
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Chitosan-Hydroxycinnamic Acids Conjugates: Emerging Biomaterials with Rising Applications in Biomedicine.

Ojeda-Hernández, Doddy Denise / Canales-Aguirre, Alejandro A / Matias-Guiu, Jordi A / Matias-Guiu, Jorge / Gómez-Pinedo, Ulises / Mateos-Díaz, Juan Carlos

International journal of molecular sciences

2022 Volume 23, Issue 20

Abstract: Over the past thirty years, research has shown the huge potential of chitosan in biomedical applications such as drug delivery, tissue engineering and regeneration, cancer therapy, and antimicrobial treatments, among others. One of the major advantages ... ...

Abstract	Over the past thirty years, research has shown the huge potential of chitosan in biomedical applications such as drug delivery, tissue engineering and regeneration, cancer therapy, and antimicrobial treatments, among others. One of the major advantages of this interesting polysaccharide is its modifiability, which facilitates its use in tailor-made applications. In this way, the molecular structure of chitosan has been conjugated with multiple molecules to modify its mechanical, biological, or chemical properties. Here, we review the conjugation of chitosan with some bioactive molecules: hydroxycinnamic acids (HCAs); since these derivatives have been probed to enhance some of the biological effects of chitosan and to fine-tune its characteristics for its application in the biomedical field. First, the main characteristics of chitosan and HCAs are presented; then, the currently employed conjugation strategies between chitosan and HCAs are described; and, finally, the studied biomedical applications of these derivatives are discussed to present their limitations and advantages, which could lead to proximal therapeutic uses.
MeSH term(s)	Chitosan/chemistry ; Biocompatible Materials/chemistry ; Coumaric Acids/therapeutic use ; Tissue Engineering ; Anti-Infective Agents/pharmacology ; Anti-Infective Agents/therapeutic use ; Anti-Infective Agents/chemistry
Chemical Substances	Chitosan (9012-76-4) ; Biocompatible Materials ; Coumaric Acids ; Anti-Infective Agents
Language	English
Publishing date	2022-10-18
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms232012473
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Editorial: COVID-19 in CNS and PNS: Basic and Clinical Focus on the Mechanisms of Infection and New Tools for the Therapeutic Approach.

Matias-Guiu, Jorge / Matias-Guiu, Jordi A / Garrido, Carmen / Pimienta, Genaro / Reyes, Patricio F / Baig, Abdul Mannan / Gomez-Pinedo, Ulises

Frontiers in neurology

2022 Volume 13, Page(s) 838227

Language	English
Publishing date	2022-03-03
Publishing country	Switzerland
Document type	Editorial
ZDB-ID	2564214-5
ISSN	1664-2295
ISSN	1664-2295
DOI	10.3389/fneur.2022.838227
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Leptin haploinsufficiency exerts sex-dependent partial protection in SOD1

Fernández-Beltrán, Luis C / Ali, Zeinab / Larrad-Sanz, Angélica / Lopez-Carbonero, Juan I / Godoy-Corchuelo, Juan M / Jimenez-Coca, Irene / Garcia-Toledo, Irene / Bentley, Liz / Gomez-Pinedo, Ulises / Matias-Guiu, Jordi A / Gil-Moreno, Maria Jose / Matias-Guiu, Jorge / Corrochano, Silvia

Scientific reports

2024 Volume 14, Issue 1, Page(s) 2671

Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by significant metabolic disruptions, including weight loss and hypermetabolism in both patients and animal models. Leptin, an adipose-derived hormone, displays ... ...

Abstract	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by significant metabolic disruptions, including weight loss and hypermetabolism in both patients and animal models. Leptin, an adipose-derived hormone, displays altered levels in ALS. Genetically reducing leptin levels (Lepob/+) to maintain body weight improved motor performance and extended survival in female SOD1G93A mice, although the exact molecular mechanisms behind these effects remain elusive. Here, we corroborated the sexual dimorphism in circulating leptin levels in ALS patients and in SOD1G93A mice. We reproduced a previous strategy to generate a genetically deficient leptin SOD1G93A mice (SOD1G93ALepob/+) and studied the transcriptomic profile in the subcutaneous adipose tissue and the spinal cord. We found that leptin deficiency reduced the inflammation pathways activated by the SOD1G93A mutation in the adipose tissue, but not in the spinal cord. These findings emphasize the importance of considering sex-specific approaches in metabolic therapies and highlight the role of leptin in the systemic modulation of ALS by regulating immune responses outside the central nervous system.
MeSH term(s)	Animals ; Female ; Humans ; Male ; Mice ; Adipose Tissue/metabolism ; Amyotrophic Lateral Sclerosis/metabolism ; Disease Models, Animal ; Haploinsufficiency ; Leptin/metabolism ; Mice, Transgenic ; Spinal Cord/metabolism ; Superoxide Dismutase/metabolism ; Superoxide Dismutase-1/genetics ; Superoxide Dismutase-1/metabolism
Chemical Substances	Leptin ; SOD1 protein, human ; Superoxide Dismutase (EC 1.15.1.1) ; Superoxide Dismutase-1 (EC 1.15.1.1) ; Lep protein, mouse ; Sod1 protein, mouse (EC 1.15.1.1)
Language	English
Publishing date	2024-02-01
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-52439-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cognitive profile in multiple sclerosis and post-COVID condition: a comparative study using a unified taxonomy.

Delgado-Alonso, Cristina / Delgado-Alvarez, Alfonso / Díez-Cirarda, María / Oliver-Mas, Silvia / Cuevas, Constanza / Montero-Escribano, Paloma / Ramos-Leví, Ana Maria / Gil-Moreno, María José / López-Carbonero, Juan Ignacio / Hermann, Bruce P / Matias-Guiu, Jorge / Matias-Guiu, Jordi A

Scientific reports

2024 Volume 14, Issue 1, Page(s) 9806

Abstract: Post-COVID condition (PCC) and multiple sclerosis (MS) share some clinical and demographic features, including cognitive symptoms and fatigue. Some pathophysiological mechanisms well-known in MS, such as autoimmunity, neuroinflammation and myelin damage, ...

Abstract	Post-COVID condition (PCC) and multiple sclerosis (MS) share some clinical and demographic features, including cognitive symptoms and fatigue. Some pathophysiological mechanisms well-known in MS, such as autoimmunity, neuroinflammation and myelin damage, have also been implicated in PCC. In this study, we aimed to compare the cognitive phenotypes of two large cohorts of patients with PCC and MS, and to evaluate the relationship between fatigue and cognitive performance. Cross-sectional study including 218 patients with PCC and 218 with MS matched by age, sex, and years of education. Patients were evaluated with a comprehensive neuropsychological protocol and were categorized according to the International Classification of Cognitive Disorders system. Fatigue and depression were also assessed. Cognitive profiles of PCC and MS largely overlapped, with a greater impairment in episodic memory in MS, but with small effect sizes. The most salient deficits in both disorders were in attention and processing speed. The severity of fatigue was greater in patients with PCC. Still, the correlations between fatigue severity and neuropsychological tests were more prominent in the case of MS. There were no differences in the severity of depression among groups. Our study found similar cognitive profiles in PCC and MS. Fatigue was more severe in PCC, but was more associated with cognitive performance in MS. Further comparative studies addressing the mechanisms related to cognitive dysfunction and fatigue may be of interest to advance the knowledge of these disorders and develop new therapies.
MeSH term(s)	Humans ; Multiple Sclerosis/complications ; Multiple Sclerosis/psychology ; Male ; Female ; Middle Aged ; Adult ; Cross-Sectional Studies ; COVID-19/complications ; COVID-19/psychology ; COVID-19/virology ; Fatigue ; Neuropsychological Tests ; Cognition ; Cognitive Dysfunction ; Depression ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2/isolation & purification
Language	English
Publishing date	2024-04-29
Publishing country	England
Document type	Journal Article ; Comparative Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-60368-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito